Global vaccination recommendations and thimerosal

Pediatrics

Volumn 131, Issue 1, 2013, Pages 149-151

  Orenstein, Walter A ^a,b   Paulson, Jerome A ^c,d   Brady, Michael T ^e   Cooper, Louis Z ^f   Seib, Katherine ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d Department of Environmental and Occupational   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; THIOMERSAL; VACCINE;

AUTISM; CONSULTATION; DEVELOPMENTAL DISORDER; DRUG COST; DRUG FORMULATION; EMERGENCY; HUMAN; NEUROTOXICITY; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VACCINATION; WORLD HEALTH ORGANIZATION;

ACADEMIES AND INSTITUTES; HUMANS; INTERNATIONAL COOPERATION; MERCURY; PEDIATRICS; THIMEROSAL;

EID: 84872836009     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-1760     Document Type: Note

References (31)

1. Bunker JP, Frazier HS, Mosteller F. Improving health: Measuring effects of medical care. Milbank Q. 1994;72(2):225-258
2. US Food and Drug Administration. Vaccines, blood & biologics: Thimerosal in vaccines questions and answers. US Department of Health and Human Services. Available at www.fda.gov/BiologicsBloodVaccines/vaccines/ questionsaboutvaccines/ucm070430. Accessed November 15, 2012
3. American Academy of Pediatrics and United States Public Health Service. Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics. 1999;104(3 pt 1):568-569
4. US Food and Drug Administration. Thimerosal in vaccines. Available at: Www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ UCM096228#t1. Accessed November 16, 2012
5. Schubert C. Pandemic blows lid off laws limiting mercury in vaccines. Nat Med. 2010;16(1):9
6. Institute of Medicine. Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academy of Sciences; 2004
7. DeStefano F. Vaccines and autism: Evidence does not support a causal association. Clin Pharmacol Ther. 2007;82(6):756-759
8. Doja A, Roberts W. Immunizations and autism: A review of the literature. Can J Neurol Sci. 2006;33(4):341-346
9. Gerber JS, Offit PA. Vaccines and autism: A tale of shifting hypotheses. Clin Infect Dis. 2009;48(4):456-461
10. Hurley AM, Tadrous M, Miller ES. Thimerosalcontaining vaccines and autism: A review of recent epidemiologic studies. J Pediatr Pharmacol Ther. 2010;15(3):173-181
11. Miller L, Reynolds J. Autism and vaccination-the current evidence. J Spec Pediatr Nurs. 2009;14(3):166-172
12. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. Pediatrics. 2004; 114(3):793-804
13. Thompson WW, Price C, Goodson B, et al Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-1292
14. Offit PA, Davis RL, Gust D. Vaccine Safety. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Saunders Elsevier; 2008
15. Pichichero ME. Safety profile of thimerosal and the safety of alternative preservatives. the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at: Www.who.int/ immunization/sage/meetings/2012/april/Pichichero-Update-on-safety.pdf. Accessed November 15, 2012
16. Mitkus R. A review of thimerosal in vaccines. Presented at the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at www.who.int/immunization/sage/meetings/2012/april/WHO- meeting-slides-Mitkus-040312.pdf. Accessed November 15, 2012
17. Pichichero ME. Perspective-Report to WHO: No New Concerns About Thimerosal Elsevier Global Medical News. MedConnect; May 10, 2012. Available at www.medconnect.com.sg/tabid/92/ct1/c45477/Perspective-Report-to-WHONo-New- Concerns-About-Thimerosal-/Default. aspx. Accessed November 15, 2012
18. American Academy of Pediatrics. Policy Statement-AAP Publications Reaffirmed and Retired. Pediatrics. 2011;127(3). Available at: Www.pediatrics.org/cgi/content/full/127/3/e857
19. Cooper LZ, Katz SL. Ban on thimerosal in draft treaty on mercury: Why the AAP's position in 2012 is so important. Pediatrics. 2013;131(1):152-153
20. World Health Organization. Meeting of Global Advisory Committee on Vaccine Safety, June 18-19, 2008. Wkly Epidemiol Rec. 2008;83(32):287-292
21. World Health Organization. Statement on thiomersal. Global Advisory Committee on Vaccine Safety. Available at: Www.who.int/vaccine-safety/topics/ thiomersal/statement-jul2006/en/index. html. Accessed November 15, 2012
22. World Health Organization. SAGE meeting of 10-April 12, 2012. www.who.int/immunization/sage/meetings/2012/april/en/index.html. Accessed November 15, 2012
23. Goverment of Chile. Timerosal: Problems, costs and solutions. Presented at the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at www.who.int/immunization/sage/meetings/2012/ april/timerosol-problems-costs-solution-de-chile. pdf. Accessed November 15, 2012
24. Deschamps I. Manufacturer perspectives on alternatives to thiomersal. Presented at the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at www.who.int/immunization/ sage/meetings/2012/april/Alternatives-Thiomersal-novartis-sanofi-pasteur.pdf. Accessed November 15, 2012
25. Battersby A, Garnett A. Indicative operational, financial and environmental impact of thiomersal-free vaccines. Presented at the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at www.who.int/immunization/sage/meetings/2012/april/ assessing-impact-battersby.pdf. Accessed November 15, 2012
26. Jadhav S. Thiomersal in vaccines: DCVMN perspective. Presented at the Strategic Advisory Group of Experts Meeting, Session: Information on Vaccines for an Intergovernmental Negotiating Committee on Mercury; April 2012; Geneva, Switzerland. Available at www.who.int/immunization/sage/meetings/2012/april/3-S- Jadhav-Thiomersalpresentation-SAGE-Final.pdf. Accessed November 15, 2012
27. World Health Organization. Strategic Advisory Group of Experts (SAGE) on Immunization. Available at: Www.who.int/immunization/sage/en. Accessed November 15, 2012
28. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012-conclusions and recommendations. Wkly Epidemiol Rec. 2012;87(21):201-216
29. American Academy of Pediatrics. Ban on all mercury-based products would risk global immunization efforts, says AAP, WHO. AAP News. Available at http://aapnews.aappublications.org/content/early/2012/06/01/aapnews. 20120601-1.full?rss=1. Accessed November 15, 2012
30. US Department of Health & Human Services. 2010 national vaccine plan. Available at: Www.hhs.gov/nvpo/vacc-plan/2010%20 Plan/nationalvaccineplan.pdf. Accessed November 15, 2012
31. Liu L, Johnson HL, Cousens S, et al Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379 (9832):2151-2161